Objective—To evaluate cross protection provided by administration of contagious ecthyma vaccines against strains of orf virus in goats.
Animals—126 Boer-Spanish crossbred goats (3 to 20 days old).
Procedures—85 goats were vaccinated with a goat-derived contagious ecthyma vaccine. Of these, 41 were challenge exposed with the virus strain for the contagious ecthyma vaccine, 40 were challenge exposed with a more virulent field strain of orf virus, and 4 were lost to predation or died. Another 41 goats were vaccinated with a vaccine produced from a more virulent field strain of orf virus; of these, 18 were challenge exposed with the virus strain of the goat-derived contagious ecthyma vaccine, 18 were challenge exposed with the more virulent field strain of orf virus, and 5 were lost to predation or died.
Results—Vaccination with the goat-derived contagious ecthyma vaccine did not significantly reduce the number of goats with lesions or lesion severity caused by challenge exposure with the more virulent field strain of orf virus. Vaccination with the vaccine produced from the more virulent field strain of orf virus significantly reduced the number of goats with lesions attributable to challenge exposure with the virus strain of the goat-derived contagious ecthyma vaccine, but it failed to significantly reduce lesion severity.
Conclusions and Clinical Relevance—Vaccination did not result in cross protection for the 2 strains of orf virus. This may have been attributable to antigenic differences and may be a factor in outbreaks of contagious ecthyma in vaccinated goats.
Objective—To determine the serologic and bacteriologic culture prevalence of Corynebacterium pseudotuberculosis infection in sheep and goats and the value of such assays for prediction of future development of caseous lymphadenitis (CL).
Animals—919 goats and sheep in 3 herds in southwest Texas.
Procedures—During an initial evaluation, serologic and bacteriologic culture status for CL was determined for all animals. Subsequently, animals were evaluated every 6 months for a 13-month period to detect external CL lesions. Affected animals in 2 herds were treated with tulathromycin or a control treatment; affected animals in 1 herd were culled. The value of assays for prediction of future development of CL lesions was determined.
Results—The serologic prevalence of CL in herds at the start of the study ranged from 7.52% to 69.54%. The bacteriologic culture prevalence of CL ranged from 0% to 6.12% at the start of the study and 0% to 9.56% at the end of the study. Synergistic hemolysin inhibition results were poor predictors of future development of CL lesions in animals during the study period; however, animals with positive bacteriologic culture results for CL were more likely to develop lesions in the future than were animals with negative bacteriologic culture results.
Conclusions and Clinical Relevance—Caseous lymphadenitis was detected in animals in this study despite prior management of affected animals in herds via culling. Use of a synergistic hemolysin inhibition test for management of CL may cause unnecessary culling of animals; treatment might allow retention of genetically valuable CL-affected animals in a herd without substantially increasing the prevalence of CL.